Recent progress in the discovery of melanin-concentrating hormone 1-receptor antagonists

Bibliography

• Schlumberger SE, Talke-Messerer C, Zumsteg U, Eberle AN. Expression of receptors for melanin-concentrating hormone (MCH) in different tissues and cell lines. J Recept Signal Transduct 2002;22(1-4):509-31
   PubMed Web of Science ®Google Scholar
• Ildiko A-Z, Khawaja X. The role of melanin-concentrating hormone in energy homeostasis and mood disorders. J Mol Neurosci 2009;39(1-2):86-98
   PubMedGoogle Scholar
• Sargent BJ, Moore NA. New central targets for the treatment of obesity. Br J Clin Pharm 2009;68(6):852-60
   PubMed Web of Science ®Google Scholar
• Nahon J-L. The melanocortins and melanin-concentrating hormone in the central regulation of feeding behavior and energy homeostasis. C R Biol 2006;329:623-38
   PubMedGoogle Scholar
• Bednarek MA. Peptide ligands for the Melanin-Concentrating Hormone (MCH) receptor 1. Curr Top Med Chem 2007;7(15):1425-32
   PubMedGoogle Scholar
• Jeon M-K, Cheon HG. Promising strategies for obesity pharmacotherapy: melanocortin-4 (MC-4) receptor agonists and melanin concentrating hormone (MCH) receptor-1 antagonists. Curr Top Med Chem 2009;9:504-38
   PubMed Web of Science ®Google Scholar
• Rivera G, Bocanegra-Garcia V, Galiano S, Melanin-concentrating hormone receptor 1 antagonists: a new perspective for the pharmacologic treatment of obesity. Curr Top Med Chem 2008;8:504-38
   Google Scholar
• Kym PR, Judd AS, Lynch JK, Lead optimization strategies and tactics applied to the discovery of melanin concentrating hormone receptor 1 antagonists. Curr Top Med Chem 2007;7:1471-88
   PubMed Web of Science ®Google Scholar
• Mendez-Andino JL, Wos JA. MCH -R1 antagonists: what is keeping most research programs away from the clinic? Drug Discov Today 2007;12(21&22):972-9
   PubMedGoogle Scholar
• McBriar MD. Recent advances in the discovery of melanin-concentrating hormone receptor antagonists. Curr Opin Drug Discov Dev 2006;9:496
   PubMedGoogle Scholar
• Qu D, Ludwig DS, Gammeltoft S, A role for melanin-concentrating hormone in the central regulation of feeding behavior. Nature 1996;380:243-7
   PubMed Web of Science ®Google Scholar
• Shimada M, Tritos NA, Lowell BB, Mice lacking melanin-concentrating hormone are hypophagic and lean. Nature 1998;396:670-4
   PubMed Web of Science ®Google Scholar
• Chambers J, Ames RS, Bergsma D, Melanin-concentrating hormone is the cognate ligand for the orphan G-protein coupled receptor SLC-1. Nature 1999;400:261-5
   PubMed Web of Science ®Google Scholar
• Saito Y, Nothacker H-P, Wang Z, Molecular characterization of the melanin-concentrating hormone receptor. Nature 1999;400:265-9
   PubMed Web of Science ®Google Scholar
• Marsh DJ, Weingarth DT, Novi DE, Melanin-concentrating hormone 1 receptor-deficient mice are are lean, hyperactive and hyperphagic and have altered metabolism. Proc Natl Acad Sci USA 2002;99:3240-5
   PubMed Web of Science ®Google Scholar
• Borowsky B, Durkin M, Ogozalek K, Antidepressant, anxiolytic and anorectic effects of a melanin-concentrating hormone-1 receptor antagonist. Nat Med 2002;8(8):825-30
   PubMed Web of Science ®Google Scholar
• Surman DS, Freeman EE, Grabowski JF, 5-(Pyridinon-1-yl)indazoles and 5-(furopyridinon-5-yl)indazoles as MCH-1 antagonists. Bioorg Med Chem Lett 2010;20:7015-19
   PubMedGoogle Scholar
• Hadden M, Deering DM, Henderson AJ, Synthesis and SAR of 4-aryl-1-(indazol-5-yl)pyridine-2(1H)ones as MCH-1 antagonists for the treatment of obesity. Bioorg Med Chem Lett 2010;20:7020-3
   PubMed Web of Science ®Google Scholar
• Henderson AJ, Deering D, Grabowski JF, Tetrahydrocarboline analogs as MCH-1 antagonists. Bioorg Med Chem Lett 2010;20:2024-7028
   Google Scholar
• Suzuki T, Kameda M, Ando M, Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists. Bioorg Med Chem Lett 2009;19:5339-45
   PubMedGoogle Scholar
• Ito M, Sakamoto M, Suzuki T, Identification and characterization of a selective radioligand for melanin concentrating hormone 1-receptor (MCH1R). Bioorg Med Chem Lett 2009;19:2835-9
   PubMed Web of Science ®Google Scholar
• Ito M, Ishihara A, Gomori A, Melanin-concentrating hormone 1-receptor antagonist suppresses body weight gain correlated with high receptor occupancy levels in diet-induced obesity mice. Eur J Pharm 2009;624:77-83
   PubMed Web of Science ®Google Scholar
• Kowalski TJ, Spar BD, Weig BD, Effects of a selective melanin-concentrating hormone 1-receptor antagonist on food intake and energy homeostasis in diet-induced obese mice. Eur J Pharmacol 2006;535:182-91
   PubMed Web of Science ®Google Scholar
• Huang CQ, Baker T, Schwarz D, 1-(4-Amino-phenyl)-pyrrolidin-3-yl-amine and 6-(3-aminopyrrolidin-1-yl)-pyridin-3-yl-amine derivatives as melaninconcentrating hormone receptor-1 antagonists. Bioorg Med Chem Lett 2005;15:3701-6
   PubMedGoogle Scholar
• Ito M, Ishihara A, Gomori A, Mechanism of the anti-obesity effects induced by a novel Melanin-concentrating hormone 1-receptor antagonist in mice. Br J Pharm 2010;159:374-83
   PubMedGoogle Scholar
• Mori M, Harada M, Terao Y, Cloning of a novel G protein-coupled receptor, SLT, a subtype of the melanin-concentrating hormone receptor. Biochem Biophys Res Commun 2001;283(5):1013-18
   PubMed Web of Science ®Google Scholar
• Wang S, Jiang B, O'Neill K, . Identification and pharmacological characterization of a novel human melanin-concentrating hormone receptor, MCH-R2. J Biol Chem 2001;276(37):34664-70
   PubMedGoogle Scholar
• Luthin DR. Anti-obesity effects of small molecule melanin-concentrating hormone receptor1 (MCHR1) antagonists. Life Sci 2007;81(6):423-40
   PubMed Web of Science ®Google Scholar
• Shimazaki T, Yoshimizu T, Shigeyuki C. Melanin-concentrating hormone MCH1 receptor antagonists. A potential new approach to the treatment of depression and anxiety disorders. CNS Drugs 2006;20(10):801-11
   PubMedGoogle Scholar
• Chaki S, Funakoshi T, Hirota-Okuno S, Anxiolytic- and antidepressant-like profile of ATC0065 and ATC0175: nonpeptidic and orally active melanin-concentrating hormone receptor 1 antagonists. J Pharmacol Exp Ther 2005;313(2):831-9
   PubMedGoogle Scholar
• Dyck B. Small molecule melanin-concentrating hormone receptor 1(MCH1R) antagonists as anxiolytic and antidepressive agents. Drug Dev Res 2005;65(4):291-300
   Google Scholar
• Ito M, Gomori A, Suzuki J, Antagonism of central melanin-concentrating hormone 1 receptor alleviates steatohepatitis in mice. J Endocr 2008;198:309-15
   PubMedGoogle Scholar
• Parks GS, Okumura SM, Gohil K, Civelli O. Mice lacking melanin concentrating hormone receptor are resistant to seizures. Neurosci Lett 2010;484:104-7
   PubMed Web of Science ®Google Scholar
• Available from: http://www.iddb.com/Thompson Current Drugs: drug report for AMG-076 2010
   Google Scholar
• Andersen D, Storz T, Liu P, Stereoselective synthesis of a MCHr1 antagonist. J Org Chem 2007;72:9648
   PubMedGoogle Scholar
• Available from: http://www.iddb.com/Thompson Current Drugs: drug report for NGD-4715 2010
   Google Scholar
• Hertzog DL, Al-Barazanji KA, Barvian KK, MCH R1 antagonists: problems and solutions. Abstracts of Papers, 240th ACS National Meeting MEDI-283; 22 – 26 August 2010; Boston, MA, United States
   Google Scholar
• Valentino MA, Lin JE, Waldman SA. Central and peripheral molecular targets for antiobesity pharmacotherapy. Clin Pharm Ther 2010;87(6):652-62
   PubMedGoogle Scholar
• Available from: http://www.iddb.com/Thompson Current Drugs: drug report for Alb127158(a) 2010
   Google Scholar
• Carpenter AJ, Herzog DL. Melanin-concentrating hormone receptor antagonists as potential antiobesity agents. Expert Opin Ther Patents 2002;12(11):1639-46
   Web of Science ®Google Scholar
• Browning A. Recent developments in the discovery of melanin-concentrating hormone antagonists: novel antiobesity agents. Expert Opin Ther Patents 2004;14(3):313-25
   Web of Science ®Google Scholar
• Dyke HJ, Ray NC. Recent developments in the discovery of MCH-1R antagonists for the treatment of obesity – an update. Expert Opin Ther Patents 2005;15(10):1303-13
   Web of Science ®Google Scholar
• Rokosz LL. Discovery and development of melanin-concentrating hormone receptor 1 antagonists for the treatment of obesity. Expert Opin Drug Discov 2007;2(10):1301-27
   PubMed Web of Science ®Google Scholar
• 7TM Pharma. WO06010446; 2006
   Google Scholar
• Sasmal PK, Sasmal S, Tirumala Rao P, Discovery of novel, orally available benzimidazoles as melanin concentrating hormone receptor 1 (MCHR1) antagonists. Bioorg Med Chem Lett 2010;20:5443-8
   PubMedGoogle Scholar
• AMRI. WO08086404; 2008
   Google Scholar
• AMRI. WO08086409; 2008
   Google Scholar
• AMRI. WO09015037; 2009
   Google Scholar
• AMRI. WO09089482; 2009
   Google Scholar
• AstraZeneca. WO06068594; 2006
   Google Scholar
• AstraZeneca. WO06130075; 2006
   Google Scholar
• AstraZeneca. WO07078251; 2007
   Google Scholar
• AstraZeneca. WO07011284; 2007
   Google Scholar
• AstraZeneca. WO07011285; 2007
   Google Scholar
• AstraZeneca. WO07011286; 2007
   Google Scholar
• AstraZeneca. WO08020799; 2008
   Google Scholar
• Banyu. WO06038680; 2006 [ US20070299070]
   Google Scholar
• Banyu. WO05085200; 2005 [ US20070208046]
   Google Scholar
• Banyu. WO07018248; 2007 [ US20100216758]
   Google Scholar
• Ando M, Sekino E, Haga Y, Discovery of novel phenethylpyridone derivatives as potent melanin-concentrating hormone 1 receptor antagonists. Bioorg Med Chem Lett 2009;19:5186-90
   PubMedGoogle Scholar
• Banyu. WO07024004; 2007 [ US20090137587]
   Google Scholar
• Banyu. WO07029847; 2007 [ US20090264426]
   Google Scholar
• Banyu. WO07142217; 2007
   Google Scholar
• Suzuki T, Moriya M, Sakamoto T, Discovery of novel spiro-piperidinederivatives as highly potent and selective melanin-concentrating hormone 1 receptor antagonists. Bioorg Med Chem Lett 2009;19:3072-7
   PubMedGoogle Scholar
• Banyu. WO04069798; 2004 [ US20060106046]
   Google Scholar
• Suzuki T, Kameda M, Ando M, Discovery of novel diarylketoxime derivatives as selective and orally active melanin-concentrating hormone 1 receptor antagonists. Bioorg Med Chem Lett 2009;19:5339-45
   PubMedGoogle Scholar
• Banyu. WO08038692; 2008 [ US20090247560]
   Google Scholar
• Banyu. WO08047544; 2008
   Google Scholar
• Banyu. WO09041567; 2009/ US20100216758; 2010
   Google Scholar
• Banyu. WO09119726; 2009
   Google Scholar
• Banyu. WO20010013595; 2010
   Google Scholar
• Biovitrum. WO06114402; 2006
   Google Scholar
• Boehringer Ingelheim. WO07048802; 2007
   Google Scholar
• Boehringer Ingelheim. WO08071646; 2008
   Google Scholar
• Boehringer Ingelheim. WO08022979; 2008
   Google Scholar
• Boehringer Ingelheim. WO09103478; 2009
   Google Scholar
• Bristol Myers Squibb. WO07050723; 2007
   Google Scholar
• Bristol Myers Squibb. WO07050726; 2007
   Google Scholar
• Bristol Myers Squibb. WO07092416; 2007
   Google Scholar
• Bristol Myers Squibb. WO08134480; 2008
   Google Scholar
• Bristol Myers Squibb. WO09009501; 2009
   Google Scholar
• Bristol Myers Squibb. WO09146365; 2009
   Google Scholar
• Bristol Myers Squibb. WO10042682; 2010
   Google Scholar
• Bristol Myers Squibb. WO10042674; 2010
   Google Scholar
• Bristol Myers Squibb. WO10047956; 2010
   Google Scholar
• Bristol Myers Squibb. WO10104818; 2010
   Google Scholar
• Bristol Myers Squibb. WO10104830; 2010
   Google Scholar
• Cerep. WO07012661; 2007
   Google Scholar
• Cerep. WO07012670; 2007
   Google Scholar
• Eli Lilly. WO06066174; 2006
   Google Scholar
• Eli Lilly. WO08076562; 2008
   Google Scholar
• Eli Lilly. WO06066173; 2006
   Google Scholar
• Eli Lilly. WO07146759; 2007
   Google Scholar
• Eli Lilly. WO07146758; 2007
   Google Scholar
• Hertzog DL, Witty DR. Biphenyl amides and isosteres as MCH R1 antagonists. Curr Top Med Chem 2007;7:1455-70
   PubMedGoogle Scholar
• GlaxoSmithKline. WO09076387; 2009
   Google Scholar
• Hoffmann La Roche. WO08065021; 2008
   Google Scholar
• Janssen. WO07071646; 2007
   Google Scholar
• Janssen. WO08068265; 2008
   Google Scholar
• Korea Research Institute. WO08140239; 2008
   Google Scholar
• Lundbeck. WO06041635; 2006
   Google Scholar
• Lundbeck. WO06041636; 2006
   Google Scholar
• Lundbeck. US20060079523; 2006
   Google Scholar
• Lundbeck. US20060079524; 2006
   Google Scholar
• Lundbeck. WO07114902; 2007
   Google Scholar
• Lundbeck. WO07114916; 2007
   Google Scholar
• Lundbeck. WO09120655; 2009
   Google Scholar
• Lundbeck. WO09137270; 2009
   Google Scholar
• Neurogen. WO06015279; 2006
   Google Scholar
• Neurogen. WO06044174; 2006
   Google Scholar
• Neurogen. WO08016811; 2008
   Google Scholar
• Pfizer. WO08041090; 2008
   Google Scholar
• Procter & Gamble. WO08002575; 2008
   Google Scholar
• Procter & Gamble. WO08001160; 2008
   Google Scholar
• Sanofi-Aventis. WO07042660; 2007
   Google Scholar
• Sanofi-Aventis. WO07042668; 2007
   Google Scholar
• Sanofi-Aventis. WO07042669; 2007
   Google Scholar
• Sanofi-Aventis. WO07093366; 2007
   Google Scholar
• Sanofi-Aventis. WO09021740; 2009
   Google Scholar
• Sanofi-Aventis. WO10092153; 2010
   Google Scholar
• Sanofi-Aventis. WO10092154; 2010
   Google Scholar
• Schering-Plough. WO06019957; 2006
   Google Scholar
• Taisho. WO06035967; 2006
   Google Scholar
• Taisho. WO05095357; 2005
   Google Scholar
• Taisho. WO04087680; 2004
   Google Scholar
• Taisho. EP01464335; 2003
   Google Scholar
• Taisho. WO08044632; 2008
   Google Scholar
• Taisho. WO10038901; 2010
   Google Scholar
• Takeda. WO09123194; 2009 Equivalent of EP2261213
   Google Scholar
• Takeda. WO10087454; 2010
   Google Scholar
• Redfern W, Carlsson L, Davis AS, Relationships between preclinical cardiac electrophysiology, clinical QT interval prolongation and torsade de pointes for a broad range of drugs: evidence for a provisional safety margin in drug development. Cardiovasc Res 2003;58(1):32-45
   PubMed Web of Science ®Google Scholar